Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TODAY: Treatment Options for Type 2 Diabetes in Adolescents and Youth
NCT00081328Phase 3Completed
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- May 2004
- Primary completion
- Feb 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of liquid metformin (Aspargo Labs) and rosiglitazone in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by National Institute of Diabetes and Digestive and Kidney Diseases. Primary endpoint: Treatment Failure (Loss of Glycemic Control) at 6.5 years. Started May 2004; status: completed.
02
Drugs
liquid metformin (Aspargo Labs)rosiglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00081328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00081328.